Items where authors include "Waters, S"

Export as [feed] Atom [feed] RSS
Number of items: 8.

Article

Howell, SJ, Casbard, A, Carucci, M et al. (14 more authors) (2022) Fulvestrant plus capivasertib versus placebo after relapse or progression on an aromatase inhibitor in metastatic, oestrogen receptor-positive, HER2-negative breast cancer (FAKTION): overall survival, updated progression-free survival, and expanded biomarker analysis from a randomised, phase 2 trial. The Lancet Oncology, 23 (7). pp. 851-864. ISSN 1470-2045

Waters, S and Palmer, H (2022) Dying at work. Work-related suicide – how does the UK regulatory context measure up? Journal of Public Mental Health, 21 (1). pp. 35-45. ISSN 1746-5729

Ahmed, WUR, Bhatia, S, McLean, KA et al. (4545 more authors) (2022) Validation of the OAKS prognostic model for acute kidney injury after gastrointestinal surgery. BJS Open, 6 (1). zrab150. ISSN 2474-9842

Waters, S (2021) Réfléchir à la portée du procès de France Télécom au Royaume-Uni. Travailler, 46. pp. 103-121. ISSN 1620-5340

Waters, S (2018) Liberalisation, surveillance and suicide at La Poste. Modern and Contemporary France, 26 (3). pp. 275-290. ISSN 0963-9489

Waters, S, Karanikolos, M and McKee, M (2016) When work kills. Journal of Public Mental Health, 15 (4). pp. 229-234. ISSN 1746-5729

Waters, S (2015) Disappearing bodies: The workplace and documentary film in an era of pure money. French Cultural Studies, 26 (3). pp. 289-301. ISSN 0957-1558

Proceedings Paper

Jones, RH, Carucci, M, Casbard, AC et al. (10 more authors) (2019) Capivasertib (AZD5363) plus fulvestrant versus placebo plus fulvestrant after relapse or progression on an aromatase inhibitor in metastatic ER -positive breast cancer (FAKTION): A randomized, double-blind, placebo-controlled, phase II trial. In: Journal of Clinical Oncology. Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), 31 May - 04 Jun 2019, Chicago, IL, USA. American Society of Clinical Oncology .

This list was generated on Mon Mar 25 01:14:34 2024 GMT.